ArticleCellular and molecular gastroenterology and hepatology2019
Differential Cell Susceptibilities to Kras
Article in Cellular and molecular gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- S100 Calcium-Binding Protein P and Cathepsin E as Key Mediators in Pancreatic Cancer Tumorigenesis.Biomedicines · 2025Article
- Interaction of the tumor suppressor SMAD4 and WNT signaling in progression to oral squamous cell carcinoma.The Journal of pathology · 2024Article
- Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges.Frontiers in endocrinology · 2024Review
- Pancreatic cancer: Advances and challenges.Cell · 2023Review
- The biology of pancreatic cancer morphology.Pathology · 2022Review
- Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes.Visceral medicine · 2022Review
- Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2022Review
- The pancreatic cancer genome revisited.Nature reviews. Gastroenterology & hepatology · 2021Review
- SOX9 modulates cancer biomarker and cilia genes in pancreatic cancer.Human molecular genetics · 2021Article
- Review
- Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice.Scientific reports · 2020Article
- Review
- Putting the Cell of Origin for Pancreatic Cancer Into its Proper Context.Cellular and molecular gastroenterology and hepatology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsActivating mutation of the KRAS gene is common in some cancers, such as pancreatic cancer, but rare in other cancers. Chronic pancreatitis is a predisposing condition for pancreatic ductal adenocarcinoma (PDAC), but how it synergizes with KRAS mutation is not known.
methodsWe used a mouse model to express an activating mutation of Kras in conjunction with obstruction of the main pancreatic duct to recapitulate a common etiology of human chronic pancreatitis. Because the cell of origin of PDAC is not clear, Kras mutation was introduced into either duct cells or acinar cells.
resultsAlthough Kras
conclusionsOne mechanism by which tissues may be susceptible or resistant to KRAS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.